Arjun V. Balar, MD, on Urothelial Cancer: Results From KEYNOTE-052
2016 ESMO CongressArjun V. Balar, MD, of the NYU Perlmutter Cancer Center, discusses preliminary phase II study findings on pembrolizumab as first-line therapy for advanced/unresectable or metastatic urothelial cancer. (Abstract LBA32)